Literature DB >> 22729401

Vaccination against rheumatic heart disease: a review of current research strategies and challenges.

Manisha Pandey1, Michael R Batzloff, Michael F Good.   

Abstract

Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are major health problems in many developing countries and Indigenous populations of developed countries. ARF and RHD are sequelae resulting from an infection of Streptococcus pyogenes. Despite advances in health care practices and technology, these diseases still pose major challenges in the communities where Streptococcus pyogenes is often endemic. Here we review and discuss the dynamic epidemiology of streptococcal infection and its associated diseases (ARF and RHD), with a focus on disease burden in temperate versus tropical regions, the tissue tropism of the organism and the efforts towards vaccine development in relation to the available animal models.

Entities:  

Year:  2012        PMID: 22729401     DOI: 10.1007/s11908-012-0263-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  80 in total

1.  Bacterial determinants of persistent throat colonization and the associated immune response in a primate model of human group A streptococcal pharyngeal infection.

Authors:  C D Ashbaugh; T J Moser; M H Shearer; G L White; R C Kennedy; M R Wessels
Journal:  Cell Microbiol       Date:  2000-08       Impact factor: 3.715

2.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 3.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

4.  Mechanism of formation of antibodies to heart tissue in immunization with group A streptococci.

Authors:  I M Lyampert; T A Danilova; N A Borodyuk; L V Beletskaya
Journal:  Folia Biol (Praha)       Date:  1966       Impact factor: 0.906

5.  Rheumatic fever following streptococcal vaccination. Report of three cases.

Authors:  B F Massell; L H Honikman; J Amezcua
Journal:  JAMA       Date:  1969-02-10       Impact factor: 56.272

6.  Regulation of capsule gene expression by group A Streptococcus during pharyngeal colonization and invasive infection.

Authors:  I Gryllos; C Cywes; M H Shearer; M Cary; R C Kennedy; M R Wessels
Journal:  Mol Microbiol       Date:  2001-10       Impact factor: 3.501

7.  Disease burden due to Streptococcus dysgalactiae subsp. equisimilis (group G and C streptococcus) is higher than that due to Streptococcus pyogenes among Mumbai school children.

Authors:  Pallaval V Bramhachari; Santosh Y Kaul; David J McMillan; Melkote S Shaila; Mohan G Karmarkar; Kadaba S Sriprakash
Journal:  J Med Microbiol       Date:  2009-10-15       Impact factor: 2.472

8.  Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice.

Authors:  P Patrick Cleary; Yury V Matsuka; Thu Huynh; Hong Lam; Stephen B Olmsted
Journal:  Vaccine       Date:  2004-10-22       Impact factor: 3.641

9.  Group A streptococcal infections in children.

Authors:  Andrew C Steer; Margaret H Danchin; Jonathan R Carapetis
Journal:  J Paediatr Child Health       Date:  2007-04       Impact factor: 1.954

10.  ANTIGENIC DIFFERENCES BETWEEN MATT HEMOLYTIC STREPTOCOCCI AND THEIR GLOSSY VARIANTS.

Authors:  R C Lancefield; E W Todd
Journal:  J Exp Med       Date:  1928-11-30       Impact factor: 14.307

View more
  5 in total

1.  The classical lancefield antigen of group a Streptococcus is a virulence determinant with implications for vaccine design.

Authors:  Nina M van Sorge; Jason N Cole; Kirsten Kuipers; Anna Henningham; Ramy K Aziz; Ana Kasirer-Friede; Leo Lin; Evelien T M Berends; Mark R Davies; Gordon Dougan; Fan Zhang; Samira Dahesh; Laura Shaw; Jennifer Gin; Madeleine Cunningham; Joseph A Merriman; Julia Hütter; Bernd Lepenies; Suzan H M Rooijakkers; Richard Malley; Mark J Walker; Sanford J Shattil; Patrick M Schlievert; Biswa Choudhury; Victor Nizet
Journal:  Cell Host Microbe       Date:  2014-06-11       Impact factor: 21.023

Review 2.  Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease.

Authors:  Bo Remenyi; Jonathan Carapetis; Rosemary Wyber; Kathryn Taubert; Bongani M Mayosi
Journal:  Nat Rev Cardiol       Date:  2013-04-02       Impact factor: 32.419

Review 3.  StreptInCor: a model of anti-Streptococcus pyogenes vaccine reviewed.

Authors:  Luiza Guilherme; Edilberto Postol; Frederico Moraes Ferreira; Lea M F DeMarchi; Jorge Kalil
Journal:  Auto Immun Highlights       Date:  2013-10-04

4.  Differing Efficacies of Lead Group A Streptococcal Vaccine Candidates and Full-Length M Protein in Cutaneous and Invasive Disease Models.

Authors:  Tania Rivera-Hernandez; Manisha Pandey; Anna Henningham; Jason Cole; Biswa Choudhury; Amanda J Cork; Christine M Gillen; Khairunnisa Abdul Ghaffar; Nicholas P West; Guido Silvestri; Michael F Good; Peter M Moyle; Istvan Toth; Victor Nizet; Michael R Batzloff; Mark J Walker
Journal:  mBio       Date:  2016-06-14       Impact factor: 7.867

Review 5.  Towards developing a vaccine for rheumatic heart disease.

Authors:  Geethanjali Devadoss Gandhi; Navaneethakrishnan Krishnamoorthy; Ussama M Abdel Motal; Magdi Yacoub
Journal:  Glob Cardiol Sci Pract       Date:  2017-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.